Posted by Michael Wonder on 18 Aug 2022
U.S. FDA accepts Astellas' new drug application for fezolinetant
18 August 2022 - If approved by the FDA, fezolinetant would be a non-hormonal treatment for moderate to severe vasomotor symptoms associated with menopause.
Astellas Pharma today announced that the U.S. FDA has accepted the company's new drug application for fezolinetant, an investigational oral, non-hormonal compound seeking approval for the treatment of moderate to severe vasomotor symptoms associated with menopause.
